Official Title
Daratumumab Subcutaneous Pre-approval Access Study
Brief Summary

The purpose of this pre-approval access (PAA) program is to provide treatment to participants with serious/life-threatening diseases or conditions.

Approved for marketing
Individual Patients

Drug: Daratumumab
Daratumumab 1800 milligram (mg) will be administered as a fixed dose by subcutaneous (SC) injection.

Eligibility Criteria

Inclusion Criteria:

-

Exclusion Criteria:

-

Eligibility Gender
All

Janssen Research & Development, LLC Clinical Trial
Study Director
Janssen Research & Development, LLC

Janssen Research & Development, LLC
NCT Number
MeSH Terms
Daratumumab
Intervention Name
Daratumumab